We will develop a general technique to improve the clinical efficacy of monoclonal antibodies. Monoclonal antibodies are being used in many clinical applications such as cancer, septic shock and transplantation. A number of clinical indications require the deletion of undesired cell types (e. g. tumor cells). Monoclonal antibodies have the specificity to locate the cell type. We will use genetic engineering to improve the effector functional activity (e. g. complement cytotoxicity) of monoclonal antibodies. If successful, this will improve the clinical use of monoclonal antibodies by not only raising the efficacy but by possibly increasing safety due to a lowered drug load.Awardee's statement of the potential commercial applications of the research: The commercial applications of genetically engineered monoclonal antibodies with greater efficacy are very broad. The invention developed could potentially impact many areas of clinical medicine which utilize monoclonal antibodies.National Cancer Institute (NCI)
